Marker Therapeutics, Inc.MRKREarnings & Financial Report
Marker Therapeutics, Inc. is a clinical-stage biotechnology firm focused on developing innovative T cell immunotherapies for cancer treatment. Its pipeline covers hematological malignancies and multiple solid tumors, operating primarily in the U.S. oncology market to address unmet medical needs for patients with limited treatment options.
MRKR Q4 FY2025 Key Financial Metrics
Revenue
$1.1M
Gross Profit
N/A
Operating Profit
$-1.9M
Net Profit
$-1.7M
Gross Margin
N/A
Operating Margin
-170.7%
Net Margin
-154.4%
YoY Growth
-51.0%
EPS
$0.02
Marker Therapeutics, Inc. Q4 FY2025 Financial Summary
Marker Therapeutics, Inc. reported revenue of $1.1M (down 51.0% YoY) for Q4 FY2025, with a net profit of $-1.7M (up 55.6% YoY) (-154.4% margin).
Key Financial Metrics
| Total Revenue | $1.1M |
|---|---|
| Net Profit | $-1.7M |
| Gross Margin | N/A |
| Operating Margin | -170.7% |
| Report Period | Q4 FY2025 |
Marker Therapeutics, Inc. Annual Revenue by Year
Marker Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.5M).
Marker Therapeutics, Inc. Quarterly Revenue & Net Profit History
Marker Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.1M | -51.0% | $-1.7M | -154.4% |
| Q3 FY2025 | $1.2M | -36.0% | $-2.0M | -162.1% |
| Q2 FY2025 | $861.2K | -26.3% | $-4.0M | -466.3% |
| Q1 FY2025 | $349.1K | -71.9% | $-4.4M | -1273.6% |
| Q4 FY2024 | $2.3M | +113.1% | $-3.8M | -170.4% |
| Q3 FY2024 | $1.9M | +647.7% | $-2.3M | -119.8% |
| Q2 FY2024 | $1.2M | +53.3% | $-2.2M | -187.5% |
| Q1 FY2024 | $1.2M | +0.8% | $-2.4M | -192.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $1.2M | $1.9M | $2.3M | $349104 | $861184 | $1.2M | $1.1M |
| YoY Growth | 0.8% | 53.3% | 647.7% | 113.1% | -71.9% | -26.3% | -36.0% | -51.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $14.1M | $11.7M | $10.9M | $22.0M | $17.0M | $14.8M | $21.7M | $19.1M |
| Liabilities | $2.3M | $2.0M | $3.5M | $3.5M | $2.5M | $4.3M | $3.3M | $2.3M |
| Equity | $11.8M | $9.7M | $7.4M | $18.6M | $14.5M | $10.5M | $18.4M | $16.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.8M | $-3.6M | $1.2M | $-4.7M | $-5.5M | $-1.9M | $-2.7M | $-1.9M |